Clinical and regulatory advisory board
An external panel of clinicians and regulatory practitioners whose role is to hold Reserve Meds to a standard beyond what any one executive team, however experienced, would hold itself to on its own.
The work of a cross-border specialty pharmacy platform is technical, is private, and touches families at difficult moments. It is the kind of work that benefits from having outside eyes on it. Our clinical and regulatory advisory board is the formal mechanism for that scrutiny. This page sets out what the board does, how it is composed, and how its input flows into our operations. It is published, in advance of members being seated, so that any advisor being invited to serve can read the terms of the engagement on our site rather than inferring them from a handshake.
The purpose of the board
The advisory board serves three functions. The first is clinical-ethics review: a named group of senior clinicians who evaluate, on a standing cadence and on individual referral, whether Reserve Meds's editorial content, engagement posture, and case-handling practices meet the ethical standard expected of a specialty pharmacy serving seriously ill patients. The second is indication-eligibility guidance: when we are considering whether to support a new therapy, a new indication, or a new destination country, the board offers a read on the clinical and regulatory appropriateness of that extension before we commit to it. The third is a regulatory watchful eye: a standing review of our compliance posture against the evolving landscape in the destination countries we serve, with the expectation that a change in pathway, authority, or statute is surfaced to the executive team through the board rather than discovered in the field.
The seats we hold
The board is structured to hold between nine and twelve seats, organised so that the weight of clinical experience is balanced by regulatory and ethics perspective. The current structure provides for seats in the following disciplines: medical oncology, haematology, rare-disease medicine, paediatric medicine, pharmacy practice, healthcare regulatory law, medical ethics, patient advocacy, and international health-systems policy. Two seats are designated for clinicians practising in our destination countries so that the lens on our work is not exclusively a US one. Seats are filled by invitation, on the recommendation of the chair of the board and with the consent of the executive team.
Rotation cadence
Members serve a three-year term, renewable once for a further three years. Terms are staggered so that no more than one-third of the board rotates off in any given year, preserving institutional memory. The chair is elected from among the seated members for a two-year term, renewable once. A member may resign at any time on written notice, and the board may, by majority vote of its seated members, recommend the removal of a member for conflict, inactivity, or conduct inconsistent with the board's charter.
What the board reviews
On a quarterly cadence, the board reviews a standing packet that includes: a summary of engagement volume and composition, with all patient-identifying information redacted; a register of indication and country extensions considered or undertaken in the period; a digest of the editorial content published in the period and the AI-review findings generated in support of it; a register of complaints, adverse events, and pharmacovigilance submissions; and a short list of open questions that the executive team wishes the board to examine. On an ad-hoc basis, the board is convened for specific referrals: a borderline indication, a novel destination, a correspondence from a regulator, or a complaint that in the view of the pharmacist-in-charge merits external review.
How the board's input flows into operations
The board's recommendations are delivered in writing, signed by the chair, and are binding on the executive team in matters of clinical ethics and indication eligibility. In other matters they are advisory; in practice, they are followed unless the executive team records a written reason for departing from them, which itself becomes a document the board reviews at its next meeting. The board's work is supported by a secretariat function inside Reserve Meds that handles scheduling, packet preparation, and action tracking; the secretariat reports administratively to the executive team and substantively to the board.
Conflicts, confidentiality, and compensation
Members serve under a written charter that includes a conflict-of-interest disclosure, renewed annually, and a confidentiality undertaking that covers all material reviewed in the course of board work. Members are compensated for their time at rates consistent with comparable external-advisor engagements in the specialty pharmacy and life-sciences sector; compensation is disclosed in summary form on this page when the first seats are filled. Members who hold a commercial interest in a therapy, a manufacturer, or a destination-country institution material to a question before the board recuse themselves from that question.
Members to be announced
Appointments are made under the board charter and a signed non-disclosure undertaking. We publish members on this page as seats are filled; names are not disclosed ahead of written acceptance. If you are a clinician or regulatory practitioner who would like to be considered for an invitation, or if you wish to nominate a colleague, please write to [email protected] with the subject line "Advisory board nomination". Nominations are reviewed by the executive team and the seated chair in the ordinary course.
Reviewed 2026-04-22 by Reserve Meds's AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.